168 related articles for article (PubMed ID: 32923395)
1. Drug-Tolerant Idling Melanoma Cells Exhibit Theory-Predicted Metabolic Low-Low Phenotype.
Jia D; Paudel BB; Hayford CE; Hardeman KN; Levine H; Onuchic JN; Quaranta V
Front Oncol; 2020; 10():1426. PubMed ID: 32923395
[TBL] [Abstract][Full Text] [Related]
2. A Fatty Acid Oxidation-dependent Metabolic Shift Regulates the Adaptation of
Aloia A; Müllhaupt D; Chabbert CD; Eberhart T; Flückiger-Mangual S; Vukolic A; Eichhoff O; Irmisch A; Alexander LT; Scibona E; Frederick DT; Miao B; Tian T; Cheng C; Kwong LN; Wei Z; Sullivan RJ; Boland GM; Herlyn M; Flaherty KT; Zamboni N; Dummer R; Zhang G; Levesque MP; Krek W; Kovacs WJ
Clin Cancer Res; 2019 Nov; 25(22):6852-6867. PubMed ID: 31375515
[TBL] [Abstract][Full Text] [Related]
3. A Nonquiescent "Idling" Population State in Drug-Treated, BRAF-Mutated Melanoma.
Paudel BB; Harris LA; Hardeman KN; Abugable AA; Hayford CE; Tyson DR; Quaranta V
Biophys J; 2018 Mar; 114(6):1499-1511. PubMed ID: 29590606
[TBL] [Abstract][Full Text] [Related]
4. A Novel Mitochondrial Inhibitor Blocks MAPK Pathway and Overcomes MAPK Inhibitor Resistance in Melanoma.
Vashisht Gopal YN; Gammon S; Prasad R; Knighton B; Pisaneschi F; Roszik J; Feng N; Johnson S; Pramanik S; Sudderth J; Sui D; Hudgens C; Fischer GM; Deng W; Reuben A; Peng W; Wang J; McQuade JL; Tetzlaff MT; Di Francesco ME; Marszalek J; Piwnica-Worms D; DeBerardinis RJ; Davies MA
Clin Cancer Res; 2019 Nov; 25(21):6429-6442. PubMed ID: 31439581
[TBL] [Abstract][Full Text] [Related]
5. ZEB1-mediated melanoma cell plasticity enhances resistance to MAPK inhibitors.
Richard G; Dalle S; Monet MA; Ligier M; Boespflug A; Pommier RM; de la Fouchardière A; Perier-Muzet M; Depaepe L; Barnault R; Tondeur G; Ansieau S; Thomas E; Bertolotto C; Ballotti R; Mourah S; Battistella M; Lebbé C; Thomas L; Puisieux A; Caramel J
EMBO Mol Med; 2016 Oct; 8(10):1143-1161. PubMed ID: 27596438
[TBL] [Abstract][Full Text] [Related]
6. Co-expression of TNF receptors 1 and 2 on melanomas facilitates soluble TNF-induced resistance to MAPK pathway inhibitors.
Sander CA; Rush EA; Shi J; Arantes LMRB; Tesi RJ; Ross MA; Calderon MJ; Watkins SC; Kirkwood JM; Ferris RL; Butterfield LH; Vujanovic L
J Transl Med; 2022 Jul; 20(1):331. PubMed ID: 35879777
[TBL] [Abstract][Full Text] [Related]
7. Role of dual specificity phosphatases (DUSPs) in melanoma cellular plasticity and drug resistance.
Singh MK; Altameemi S; Lares M; Newton MA; Setaluri V
Sci Rep; 2022 Aug; 12(1):14395. PubMed ID: 35999349
[TBL] [Abstract][Full Text] [Related]
8. Single-Cell Profiling Reveals Metabolic Reprogramming as a Resistance Mechanism in
Waldschmidt JM; Kloeber JA; Anand P; Frede J; Kokkalis A; Dimitrova V; Potdar S; Nair MS; Vijaykumar T; Im NG; Guillaumet-Adkins A; Chopra N; Stuart H; Budano L; Sotudeh N; Guo G; Grassberger C; Yee AJ; Laubach JP; Richardson PG; Anderson KC; Raje NS; Knoechel B; Lohr JG
Clin Cancer Res; 2021 Dec; 27(23):6432-6444. PubMed ID: 34518309
[TBL] [Abstract][Full Text] [Related]
9. Vemurafenib resistance reprograms melanoma cells towards glutamine dependence.
Hernandez-Davies JE; Tran TQ; Reid MA; Rosales KR; Lowman XH; Pan M; Moriceau G; Yang Y; Wu J; Lo RS; Kong M
J Transl Med; 2015 Jul; 13():210. PubMed ID: 26139106
[TBL] [Abstract][Full Text] [Related]
10. Recurrent Tumor Cell-Intrinsic and -Extrinsic Alterations during MAPKi-Induced Melanoma Regression and Early Adaptation.
Song C; Piva M; Sun L; Hong A; Moriceau G; Kong X; Zhang H; Lomeli S; Qian J; Yu CC; Damoiseaux R; Kelley MC; Dahlman KB; Scumpia PO; Sosman JA; Johnson DB; Ribas A; Hugo W; Lo RS
Cancer Discov; 2017 Nov; 7(11):1248-1265. PubMed ID: 28864476
[TBL] [Abstract][Full Text] [Related]
11. Exploiting Drug Addiction Mechanisms to Select against MAPKi-Resistant Melanoma.
Hong A; Moriceau G; Sun L; Lomeli S; Piva M; Damoiseaux R; Holmen SL; Sharpless NE; Hugo W; Lo RS
Cancer Discov; 2018 Jan; 8(1):74-93. PubMed ID: 28923912
[TBL] [Abstract][Full Text] [Related]
12. Notch signaling activation induces cell death in MAPKi-resistant melanoma cells.
Mikheil DM; Prabhakar K; Arshad A; Rodriguez CI; Newton MA; Setaluri V
Pigment Cell Melanoma Res; 2019 Jul; 32(4):528-539. PubMed ID: 30614626
[TBL] [Abstract][Full Text] [Related]
13. GJB5 association with BRAF mutation and survival in cutaneous malignant melanoma.
Scatolini M; Patel A; Grosso E; Mello-Grand M; Ostano P; Coppo R; Vitiello M; Venesio T; Zaccagna A; Pisacane A; Sarotto I; Taverna D; Poliseno L; Bergamaschi D; Chiorino G
Br J Dermatol; 2022 Jan; 186(1):117-128. PubMed ID: 34240406
[TBL] [Abstract][Full Text] [Related]
14. Targeting mitochondrial biogenesis to overcome drug resistance to MAPK inhibitors.
Zhang G; Frederick DT; Wu L; Wei Z; Krepler C; Srinivasan S; Chae YC; Xu X; Choi H; Dimwamwa E; Ope O; Shannan B; Basu D; Zhang D; Guha M; Xiao M; Randell S; Sproesser K; Xu W; Liu J; Karakousis GC; Schuchter LM; Gangadhar TC; Amaravadi RK; Gu M; Xu C; Ghosh A; Xu W; Tian T; Zhang J; Zha S; Liu Q; Brafford P; Weeraratna A; Davies MA; Wargo JA; Avadhani NG; Lu Y; Mills GB; Altieri DC; Flaherty KT; Herlyn M
J Clin Invest; 2016 May; 126(5):1834-56. PubMed ID: 27043285
[TBL] [Abstract][Full Text] [Related]
15. T-type calcium channel inhibition restores sensitivity to MAPK inhibitors in de-differentiated and adaptive melanoma cells.
Granados K; Hüser L; Federico A; Sachindra S; Wolff G; Hielscher T; Novak D; Madrigal-Gamboa V; Sun Q; Vierthaler M; Larribère L; Umansky V; Utikal J
Br J Cancer; 2020 Mar; 122(7):1023-1036. PubMed ID: 32063604
[TBL] [Abstract][Full Text] [Related]
16. Metabolic Plasticity of Melanoma Cells and Their Crosstalk With Tumor Microenvironment.
Avagliano A; Fiume G; Pelagalli A; Sanità G; Ruocco MR; Montagnani S; Arcucci A
Front Oncol; 2020; 10():722. PubMed ID: 32528879
[TBL] [Abstract][Full Text] [Related]
17. Metabolic targeting synergizes with MAPK inhibition and delays drug resistance in melanoma.
Brummer C; Faerber S; Bruss C; Blank C; Lacroix R; Haferkamp S; Herr W; Kreutz M; Renner K
Cancer Lett; 2019 Feb; 442():453-463. PubMed ID: 30481565
[TBL] [Abstract][Full Text] [Related]
18. Clinical, molecular, metabolic, and immune features associated with oxidative phosphorylation in melanoma brain metastases.
Fischer GM; Guerrieri RA; Hu Q; Joon AY; Kumar S; Haydu LE; McQuade JL; Vashisht Gopal YN; Knighton B; Deng W; Hudgens CW; Lazar AJ; Tetzlaff MT; Davies MA
Neurooncol Adv; 2021; 3(1):vdaa177. PubMed ID: 33575655
[TBL] [Abstract][Full Text] [Related]
19. Dependence On Glycolysis Sensitizes BRAF-mutated Melanomas For Increased Response To Targeted BRAF Inhibition.
Hardeman KN; Peng C; Paudel BB; Meyer CT; Luong T; Tyson DR; Young JD; Quaranta V; Fessel JP
Sci Rep; 2017 Feb; 7():42604. PubMed ID: 28205616
[TBL] [Abstract][Full Text] [Related]
20. Metabolic flexibility in melanoma: A potential therapeutic target.
Ruocco MR; Avagliano A; Granato G; Vigliar E; Masone S; Montagnani S; Arcucci A
Semin Cancer Biol; 2019 Dec; 59():187-207. PubMed ID: 31362075
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
